Outcomes in patients with cardiac amyloidosis undergoing heart transplantation: the eurotransplant experience.
Martin J KrausJacqueline M SmitsAnna L MeyerAgita StrelnieceArne van KinsUdo BoekenAlexander ReineckeZdenek ProvaznikOliver Van CaenegemArnaud AncionMichael Berchtold-HerzJohan J A Van CleemputAxel HaverichGuenther LauferJan GummertMatthias KarckGregor WarneckePhilip W RaakeNorbert FreyMichael M KreusserPublished in: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2023)
HTX is a viable treatment option for patients at an advanced stage of cardiac amyloidosis as overall survival after transplantation has improved in the modern age. Patients at a very advanced stage of the disease, indicated by low serum albumin and blood pressure, show worse outcomes following HTX. Optimal timing and careful patient selection may therefore be particularly important to further improve post-HTX survival in amyloidosis patients.